Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,032 | 52,154 | -33,361 | 57,138 | -2,985 |
| Depreciation Amortization | 34,394 | 35,443 | 52,284 | 67,749 | 52,522 |
| Income taxes - deferred | -15,800 | 11,696 | 20,723 | -8,618 | -19,053 |
| Accounts receivable | -6,459 | -2,601 | 55,319 | -28,616 | -26,061 |
| Other Working Capital | 19,356 | -34,402 | 65,677 | -57,004 | -11,673 |
| Other Operating Activity | 69,588 | -12,713 | -22,792 | 48,149 | 61,836 |
| Operating Cash Flow | $97,047 | $49,577 | $137,850 | $78,798 | $54,586 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 36,114 | 67,403 | 182,415 | 40,010 | 616,171 |
| PPE Investments | -19,640 | -53,849 | -17,923 | -8,761 | -4,458 |
| Net Acquisitions | -91,996 | -10,405 | N/A | N/A | -382,823 |
| Purchase Of Investment | -998 | -15,249 | N/A | N/A | -500 |
| Purchase Sale Intangibles | 7,429 | 418 | 92 | 494 | 1,358 |
| Other Investing Activity | -67,144 | 418 | -868 | -726 | 3,258 |
| Investing Cash Flow | $-143,664 | $-11,682 | $163,624 | $30,523 | $231,648 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 0 | 202 | 18,938 | N/A |
| Debt Repayment | N/A | -76,854 | -260,949 | -155,760 | -222,209 |
| Common Stock Issued | 102,728 | 22,448 | 3,232 | 33,763 | 3,017 |
| Common Stock Repurchased | N/A | N/A | N/A | -18,446 | -77,998 |
| Other Financing Activity | -5,587 | -5,541 | -18,475 | -16,256 | -13,355 |
| Financing Cash Flow | $97,141 | $-59,947 | $-275,990 | $-137,761 | $-310,545 |
| Exchange Rate Effect | -1,171 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 22,954 | 45,006 | 19,522 | 47,962 | 72,273 |
| End Cash Position | 72,307 | 22,954 | 45,006 | 19,522 | 47,962 |
| Net Cash Flow | $49,353 | $-22,052 | $25,484 | $-28,440 | $-24,311 |
| Free Cash Flow | |||||
| Operating Cash Flow | 97,047 | 49,577 | 137,850 | 78,798 | 54,586 |
| Capital Expenditure | -19,640 | -53,849 | -17,923 | -8,761 | -4,458 |
| Free Cash Flow | 77,407 | -4,272 | 119,927 | 70,037 | 50,128 |